Compare GRDN & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRDN | VCEL |
|---|---|---|
| Founded | 2004 | 1989 |
| Country | United States | United States |
| Employees | 3400 | 398 |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | N/A | 1996 |
| Metric | GRDN | VCEL |
|---|---|---|
| Price | $33.37 | $31.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $33.33 | ★ $58.50 |
| AVG Volume (30 Days) | 177.2K | ★ 416.0K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | $1.13 | $19.09 |
| Revenue Next Year | $9.97 | $17.96 |
| P/E Ratio | $117.77 | ★ $102.78 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $19.17 | $29.24 |
| 52 Week High | $37.43 | $48.75 |
| Indicator | GRDN | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.23 | 32.11 |
| Support Level | $28.07 | $31.34 |
| Resistance Level | $34.98 | $38.48 |
| Average True Range (ATR) | 1.63 | 1.39 |
| MACD | -0.12 | -0.40 |
| Stochastic Oscillator | 46.46 | 4.88 |
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.